Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 3Myeloproliferative Disorders 3Solid Tumors 1Recurrence 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Fulvestrant 3Alpelisib 3duvelisib 2Cetuximab 2volagidemab 1talazoparib 1ruxolitinib 1parsaclisib 1olaparib 1obinutuzumab 1lorlatinib 1encorafenib 1dapagliflozin 1cobimetinib 1chiauranib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1NVP-BKM120 1Drug Therapy 1CYH33 1Aspirin 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × parsaclisib × Clear all
NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡